Publications by authors named "Marc A Labroli"

Claim this Profile
D
Discovery of potent wall teichoic acid early stage inhibitors.
Marc A Labroli, John P Caldwell, Christine Yang, Sang Ho Lee, Hao Wang

Bioorg Med Chem Lett· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.
Marc A Labroli, Michael P Dwyer, Ruichao Shen, Janeta Popovici-Muller, Qinglin Pu

Bioorg Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.
Jayaram R Tagat, Stuart W McCombie, Dennis Nazareno, Marc A Labroli, Yushi Xiao

J Med Chem· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
10-Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-formyl-DDACTHF): a potent cytotoxic agent acting by selective inhibition of human GAR Tfase and the de novo purine biosynthetic pathway.
Thomas H Marsilje, Marc A Labroli, Michael P Hedrick, Qing Jin, Joel Desharnais

Bioorg Med Chem· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis